Hims & Hers Health Faces Regulatory Challenges Amid FDA Scrutiny

Hims & Hers Health shares fell 8% premarket due to FDA scrutiny over marketing a cheaper version of Novo Nordisk's semaglutide weight-loss drug. The telehealth platform has 2 million subscribers and offers various healthcare services and products. Despite robust revenue growth, the company faces challenges with a modest net margin, high leverage, and potential financial manipulation. The stock trades with a high P/E ratio and P/B ratio, but technical indicators suggest it may be oversold.